Incannex Healthcare (IXHL) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Incannex Healthcare (IXHL) over the past year, losing 50.1% versus a loss of 75.8%. Nasus Pharma is the larger company by market cap ($42.5 million vs $40.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | NSRX |
|---|---|---|
| Share price | $3.20 | $3.63 |
| Market cap | $40.14M | $42.52M |
| 1-day change | +0.63% | -3.84% |
| YTD return | -70.39% | -60.33% |
| 1-year return | -75.80% | -50.07% |
| EPS (TTM) | $-1.66 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $9.50 |
| 52-week low | $2.49 | $1.98 |
| Distance from 52-week high | -78.54% | -61.79% |
| Average volume | 98.82K | 16.09K |
| Shares outstanding | 12.54M | 11.71M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NSRX has outperformed IXHL by 25.7 percentage points over the past year.
IXHL vs NSRX FAQ
Which is bigger, Incannex Healthcare or Nasus Pharma?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $40.14M for Incannex Healthcare (IXHL).
Which stock has performed better over the past year, IXHL or NSRX?
NSRX returned -50.07% over the past 12 months, compared with -75.80% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.